Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KPL-387

Other · developed by Kiniksa Pharmaceuticals International

Phase 2/3 Most advanced trial
KNSA Developer
1 Registered trials

What is KPL-387?

KPL-387 is a drug administered by subcutaneous injection. It is studied in pericarditis, including acute and recurrent pericarditis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
Kiniksa Pharmaceuticals International, plc (KNSA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07010159 Phase 2/3 Pericarditis Recruiting KNSA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PericarditisPericarditis AcuteRecurrent Pericarditis

More from Kiniksa Pharmaceuticals International

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KNSA page.

Follow KNSA, the company behind KPL-387

See KNSA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KNSA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.